## 6-12 Month Target Price for Summit Therapeutics (SMMT)
Analyst forecasts for Summit Therapeutics (NASDAQ: SMMT) over the next 6-12 months are generally bullish, with price targets concentrated in the $30 to $44 range:
– **WallStreetZen** reports a 1-year price target of $36.67[1].
– **TradingView** lists an average analyst price target of $36.56, with a maximum estimate of $44.00 and a minimum of $30.00[2].
– **TipRanks** provides an average target of $38.50, with a high of $44.00 and a low of $30.00[4].
– **Public.com** notes an average analyst forecast of $30.87 for 2025[3].
This consensus implies upside potential compared to the current price of $26.21 as of May 30, 2025.
### Comparative Analyst Targets
| Source | Low ($) | Average ($) | High ($) |
|—————|———|————-|———-|
| TradingView | 30.00 | 36.56 | 44.00 |
| TipRanks | 30.00 | 38.50 | 44.00 |
| WallStreetZen | — | 36.67 | — |
| Public.com | — | 30.87 | — |
| Gov.Capital | — | 21.79* | — |
*Note: Gov.Capital provides a notably lower and more bearish estimate, forecasting $21.79 in one year, suggesting downside risk based on its own algorithm[5].
—
## Summary
Most analyst estimates for SMMT place the 6-12 month target price in the **$30 to $44 range**, with the consensus clustering around **$36–$38**. This indicates a potential upside of 14% to 68% from the current price of $26.21, though some outlier forecasts suggest possible downside.
These targets likely reflect recent positive clinical data (as referenced in the linked press release), strong analyst sentiment, and buy ratings from the majority of covering banks and research firms[2][3][4].
As always, investors should consider both the bullish consensus and the outlier downside risk before making decisions.